PCI Pharma Services Announces First-of-Its-Kind Clinical Center of Excellence in Boston Area

Center Establishes Operations in Northeast Region to Support Growing Market

PHILADELPHIA--(BUSINESS WIRE)--PCI Pharma Services (PCI), a leading global CDMO, today announced the construction of a new Clinical Center of Excellence in Bridgewater, Massachusetts providing clinical storage, distribution and packaging to meet the growing New England clinical supply market demands. PCI is the first global CDMO with integrated end-to-end capabilities to build such a center, with a strong focus on cold chain capabilities, in New England. This major investment will allow PCI to be closer to its clients in the tri-state area and engage with more than a thousand new clients in Boston/Cambridge, the nation’s top biopharma cluster.[i] This news comes after PCI’s recent announcement that it has signed a definitive agreement to acquire LSNE, a premier contract development and manufacturing organization headquartered in Bedford, New Hampshire.

“The biotech and pharmaceutical industries have been rapidly expanding in the Northeast, especially Boston, in the last few years, and this new Clinical Center of Excellence and our recent definitive agreement to acquire LSNE, will create more convenience and efficiencies for our Northeast clients by offering them a center that combines a local feel and global capabilities,” says Brian Keesee, Vice President and General Manager, Global Operations and Supply of Clinical Services, PCI Pharma Services. “This expansion is part of our larger strategy to serve biopharmaceutical clients by providing a facility that can service their needs within a relatively short driving distance, while adding to our global footprint.”

The 50,000-square-foot center is currently under construction with an expected completion of Summer 2022. Over the last 18 months, PCI has invested heavily in its global clinical sites including San Diego, Rockford, Melbourne and Berlin as part of its global clinical expansion in all services. This includes investing in new facilities, refrigerators and freezers, increasing capacity, and adding new storage conditions in service to both large and small molecule compounds.

“Our decentralized global offering that features several smaller hubs around the world is a key reason why we’re a leader in the clinical trials space,” says Salim Haffar, CEO, PCI Pharma Services. “This center will localize PCI’s global capabilities in the Boston area, providing our Northeast clients with critical services to facilitate the packaging and distribution of life-changing treatments.”

About PCI Pharma Services

PCI is as a leading global CDMO, providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 50 successful product launches each year and over five decades in the healthcare services business. We currently have 25 sites across six countries (Australia, Canada, U.S., Ireland, Wales and Germany) and over 3,800 employees that work to bring life-changing therapies to patients. Leading technology and continued investment enable us to address global development needs throughout the product life cycle – from manufacturing capabilities in complex formulations, high potency and lyophilization through the clinical trial supply chain and into commercialization. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives. For more information, please visit pciservices.com.

[i]

Ty Guzman-Touchberry, WE Communications
tgtouchberry@we-worldwide.com